Corixa expects Bexxar advisory cmte. review
Executive Summary
Corixa expects to present Bexxar (tositumomab) to FDA's Oncologic Drug Advisory Committee before the end of the year. The committee has cancelled its Sept. 23 meeting date, but is tentatively scheduled to reconvene Dec. 17 and 18. Corixa requested the review in its appeal of a March 12 "complete review" letter for the non-Hodgkin's lymphoma therapy (1"The Pink Sheet" July 1, In Brief)...
You may also be interested in...
GSK/Corixa Bexxar NDA
Corixa/GlaxoSmithKline's Bexxar (tositumomab) could receive review for treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma by FDA's Oncologic Drugs Advisory Committee at the tentatively scheduled Sept. 23-24 meeting. Corixa requested committee review of the drug in its appeal of a March 12 "complete review" letter (1"The Pink Sheet" May 20, In Brief)...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.